Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2024-06-21 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company regarding changes in the pledge status of shares held by a major shareholder. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, and the implications of these pledges on company operations and control. There is no financial statement, earnings data, or management discussion of financial results. The document is not a report but an announcement about share pledge changes, which is a form of major shareholding notification or related shareholder information. Given the content focuses on shareholder share pledge changes, the most appropriate classification is Major Shareholding Notification (MRQ). The document length is short and it is a direct announcement, not a report or certification, so it does not fit into regulatory filings or report publication announcements.
2024-06-21 Chinese
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in shareholder stock pledge status, specifically detailing the pledge of shares by a major shareholder and related parties. It includes data on the number of shares pledged, pledge ratios, and risk assessments related to the pledges. There is no financial statement, earnings data, or management discussion of financial results. The document is a regulatory disclosure about share pledge changes, which fits the category of a Major Shareholding Notification or related shareholder pledge announcements. Given the content focuses on shareholder share pledge changes, the most appropriate classification is Major Shareholding Notification (MRQ). The document length is short and it is not an announcement of a report publication or certification, so it is not RPA or RNS. Therefore, the classification is MRQ with high confidence.
2024-06-20 Chinese
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2024 first extraordinary general meeting of shareholders of Betta Pharmaceuticals Co., Ltd. It details the meeting date, voting procedures, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or detailed report content, only the official voting results and meeting summary. The document length is short (1876 characters) and it serves as a formal announcement of voting results rather than the full meeting materials or reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-06-19 Chinese
国浩律师（杭州）事务所关于贝达药业股份有限公司2024年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of Betta Pharmaceuticals' 2024 First Extraordinary General Meeting (临时股东大会). It details the legal compliance of the meeting's call, attendance qualifications, agenda items, voting procedures, and results. The document does not contain financial statements or management discussion of financial results, nor is it a report publication announcement. It is a legal opinion on the shareholder meeting and its voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4597 characters, which is sufficient to contain detailed voting results and legal opinions rather than a brief announcement. Therefore, the best classification is DVA with high confidence.
2024-06-19 Chinese
公司章程修订对照表
Governance Information Classification · 95% confidence The document is a comparison table showing proposed amendments to the company's articles of association (章程修订对照表). It discusses revisions to the company's business scope and states that these amendments will be submitted to the 2024 first extraordinary shareholders' meeting for approval. The document is issued by the board of directors and dated May 31, 2024. This is a governance-related document concerning internal rules and company bylaws, not a financial report or announcement of voting results. It is not a full annual or interim report, nor a proxy or voting result announcement. Therefore, it fits best under Governance Information (CGR). The document length is short and focused on governance changes, supporting this classification.
2024-05-31 Chinese
贝达药业股份有限公司章程（2024年5月）
Governance Information Classification · 100% confidence The document is titled "贝达药业股份有限公司章程" which translates to "Betta Pharmaceuticals Co. Ltd. Articles of Association" or "Company Bylaws." It contains detailed chapters on company organization, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and other governance matters. The content is focused on the internal rules, structure, and governance practices of the company rather than financial results, meeting announcements, or voting results. It is a comprehensive governance document that sets out the company's constitution and operational framework. Therefore, it fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2024-05-31 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.